the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), the first
and only testosterone nasal gel for replacement therapy in adult males for conditionsassociated with a and only testosterone nasal gel for replacement therapy in adult males for
conditions associated with a and only testosterone nasal gel for replacement therapy in adult
males for conditions associated with a and only testosterone nasal gel for replacement
therapy in adult males for conditions associated with a and only testosterone nasal gel for
replacement therapy in adult males for conditions associated with a and only testosterone
nasal gel for replacement therapy in adult males for conditions associated with a and only
testosterone nasal gel for replacement therapy in adult males for conditions associated with
a deficiency or absence of endogenous testosterone. Natesto is self-administered via a
nasal applicator thereby .
uses and indications :
Primary hypogonadism (congenital or
acquired):testicular failure due to conditions
such ascryptorchidism, bilateral torsion,
orchitis, vanishingtestis syndrome,
orchiectomy, Klinefelter's
syndrome,chemotherapy, or toxic damage from
alcohol or heavy metals. These men usually have low serum testosterone concentrations
and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the
normal range.Hypogonadotropic hypogonadism (congenital or acquired): idiopathic
gonadotropin or luteinizinghormone-releasing hormone (LHRH) deficiency or pituitary-
hypothalamic injury from tumors, trauma, orradiation. These men have low testosterone
serum concentrations but have gonadotropins in the normal or low range.
.2 pump actuation per nostril administered intranasally three times daily for a total daily
dose of 33 mg.
The recognized side effects:
prostate specific antigen (PSA) increased, headache, rhinorrhea, epistaxis, nasal discomfort,
nasopharyngitis, upper respiratory tract infection (URI), sinusitis, bronchitis
No comments:
Post a Comment